It is known that the level of interleukin-6 (IL-6) is higher in patients with active Behcet's disease (BD) than in those with inactive disease. Herpes simplex virus (HSV) type 1 inoculation of the earlobes of ICR mice resulted in the development of BD-like symptoms. To find out whether downregulation of IL-6 would affect the symptoms of BD, IL-6 small interfering RNA (siRNA) was administered to a BD mouse model. IL-6 siRNA was intraperitoneally injected into BD mice to downregulate IL-6 (n ¼ 9). IL-6 siRNA injection downregulated serum IL-6 level (118.9±114.4 pg ml
Introduction
Interleukin (IL)-6 is a multifunctional cytokine secreted by lymphoid cells (T cells, B cells) and many nonlymphoid cells, including macrophages, bone marrow stromal cells, fibroblasts, keratinocytes, mesangium cells, astrocytes and endothelial cells, and involved in the regulation of immune response and inflammation. [1] [2] [3] [4] IL-6 is highly elevated in the culture supernatants of peripheral blood mononuclear cells of patients with active Behcet's disease (BD), 5 cerebrospinal fluid of patients with neuro-BD 6 and BD with ocular involvement. 7 Behcet's disease is a chronic multisystemic disorder with arthritic, gastrointestinal, mucocutaneous, ocular, vascular and central nervous systems involved. This disease takes a chronic course with periodic exacerbations and progressive deterioration. 8, 9 The etiology of BD is unclear, but viral infection has long been postulated as one of the main factors. Since Hulusi Behcet first proposed a viral etiology, 10 the viral hypothesis has been verified by detection of herpes simplex virus (HSV) type 1 in saliva, 11 intestinal ulcers 12 and genital ulcers 13, 14 of patients with BD. Subsequent to this finding, HSV inoculation of the earlobes of ICR mice resulted in the development of BD-like symptoms. 15 Manifestations in mice after HSV inoculation included multiple symptoms such as oral ulcers, genital ulcers, skin ulcers, eye symptoms, gastrointestinal ulcers, arthritis and neural involvement, as well as skin crusting. The frequency of these symptoms is similar to that of patients with BD. 16 No laboratory marker has been widely accepted for follow-up of disease activity in BD. To date, increased serum levels of cytokines, such as IL-6, have been proposed as disease activity markers. However, recent studies have shown contradictory results regarding IL-6. 5, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In this study, we have examined the upregulated expressions of IL-6 of BD mice and used small interfering RNAs (siRNAs) to reduce overexpression of IL-6 and found that reducing IL-6 expression by siRNA can affect regulatory T cells, Th17 cells and symptoms in BD mice.
Results

IL-6 levels in BD mice compared with BD asymptomatic mice
Serum IL-6 levels in BD mice were significantly higher than those in BDN mice (BD Normal, HSV was inoculated but no symptomatic mice) (420.9 ± 260.2 vs 78.7±97.3, P ¼ 0.007, n ¼ 7 in each group) ( Figure 1A ). IL-6 mRNA expression of spleen tissues ( Figure 1Ba ) and liver tissues (Figure 1Bb ) from BD mice was also higher than that in BDN mice (BD and BDN were age-matched).
IL-6 siRNA effectively downregulates IL-6 in vivo in normal healthy mice
To examine the effect of IL-6 siRNA in vitro, IL-6 siRNA was transfected to primary macrophages collected from the peritoneal lavage of normal mice. In 24 h of cultureconditioned media, the IL-6 protein level was 16.53 ± 12.65 pg ml À1 in scramble siRNA (a negative control for siRNA) transfected groups, compared with 5.88 ± 5.07 pg ml À1 in the IL-6 siRNA-transfected groups (P ¼ 0.16). In 48 h, the level was 22.92±14.02 pg ml À1 in scramble siRNA-transfected groups, compared with 8.12±8.70 pg ml À1 in the IL-6 siRNA-transfected groups (P ¼ 0.05). Thus, the IL-6 protein level was higher in conditioned media from macrophages culture of scramble siRNA-treated groups than in that of IL-6 siRNAtreated groups.
On the basis of in vitro experiments, IL-6 siRNA was applied to in vivo normal mice. As seen in Figure 2a , serum IL-6 level was increased in an age-dependent manner in ICR mice and IL-6 siRNA injection downregulated the serum level of IL-6 in all age groups. In 8-week-old mice, the IL-6 protein concentration level was 41.5 ± 14.1 pg ml À1 in control-injected mice and 13.0±3.5 pg ml À1 in IL-6 siRNA-injected mice (n ¼ 9 in each group, P ¼ 0.00002). In 9-month-old mice, the IL-6 level was 35.6±20.4 pg ml À1 in control-injected mice and 10.1 ± 6.8 pg ml À1 in IL-6 siRNA-injected mice (n ¼ 8 in each group, P ¼ 0.038). In 12-month-old mice, the IL-6 level was 246.9 ± 31.9 pg ml À1 in control-injected mice and 120.3±25.4 pg ml À1 in IL-6 siRNA-injected mice (n ¼ 4 in each group, P ¼ 0.36). In 14-month-old mice, the serum level of IL-6 was 1189.6±390.2 pg ml À1 in controlinjected mice and 222.9 ± 81.7 pg ml À1 in IL-6 siRNAinjected mice (n ¼ 5 in each group, P ¼ 0.003). Thus, a single injection of siRNA significantly decreased the IL-6 serum level, which was maintained unchanged in 8-week-old to 9-month-old mice, however, the level increased steeply in 12-month-old mice.
To explore the duration of effectiveness of siRNA, IL-6 siRNA was injected into normal healthy mice. IL-6 siRNA injection effectively maintained the downregulation of IL-6 in 12-month-old mice. At 1-3 days after a single injection of 1.5 mg of IL-6 siRNA, serum levels were analyzed by enzyme-linked immunosorbent assay (ELISA). On day 1, the serum level of IL-6 was 125.1±10.2 pg ml
À1
, compared with 248.6±13.8 pg ml À1 on day 0 (Po0.0001). On days 2 and 3, serum levels of IL-6 were 104.2±9.4 pg ml À1 (Po0.0001) and 261.7 ± 25.2 pg ml
, respectively (P ¼ 0.9). On day 3, the IL-6 level rebounded to the level similar to day 0 (n ¼ 5 per group) (Figure 2b ).
To ascertain whether repeated administration can reduce the IL-6 level more efficiently, single or repeated administration of IL-6 siRNA to normal healthy mice was carried out. Thus, mice received a single injection or four injections of 1.5 mg IL-6 siRNA with 3-day intervals. The serum was collected by retro-orbital bleeding technique before injection and 2 days after last injection of IL-6 siRNA. ELISA revealed that the serum IL-6 level after four times repeat treatment with IL-6 siRNA was not significantly different from that after one-time treatment (Figure 2c ). In this experiment, 14-month-old mice were used. In the one-time injection group, the serum IL-6 level was 1414.9 ± 223.5 pg ml À1 before the siRNA injection. Two days after the one-time injection of IL-6 siRNA, the IL-6 level was 313.0 ± 117.2 pg ml À1 (n ¼ 4, P ¼ 0.0002). In the four times injection group, the serum level of IL-6 was 1624.6 ± 314.3 pg ml À1 before the siRNA injection. Two days later, after the fourth injection of IL-6 siRNA, the serum IL-6 level was 271.8±92.4 pg ml À1 (n ¼ 4, P ¼ 0.0001). One-time injection and four times injection were not statistically different in reduction of the IL-6 level (P ¼ 0.6).
IL-6 siRNA was effective in downregulating IL-6 in BD mice
Interleukin-6 siRNA at a dose of 1.5 mg was intraperitoneally administered to BD mice with jetPEI. IL-6 siRNA-injected mice and scramble siRNA-injected mice were age-matched. Serum was collected on day 4 after a single injection of siRNA and analyzed by ELISA. The IL-6 expression levels were as follows: 420.9 ± 260.2 pg ml
À1
for the BD mice (n ¼ 8), 78.7 ± 97.3 pg ml À1 for the BDN mice (n ¼ 6), 439.4 ± 378.0 pg ml
for the scramble siRNA-injected BD mice (n ¼ 6) and 118.9 ± 114.4 pg ml
for the IL-6 siRNA-injected BD mice (n ¼ 6) (BD vs BDN: P ¼ 0.007, BD vs IL-6 siRNA-injected BD: P ¼ 0.01, scramble siRNA-injected BD vs IL-6 siRNA-injected BD: P ¼ 0.04) (Figure 3a ). Splenocytes were isolated from each group and applied to reverse transcription (RT)-PCR. RORgt, an orphan nuclear receptor that Serum TNFa and TGFb levels were also regulated by IL-6 siRNA injection into BD mice Tumor necrosis factor-a (TNFa) is a potent paracrine and endocrine mediator of inflammatory and immune functions. Overexpression of TNFa has been implicated in acute and chronic inflammatory diseases such as rheumatoid arthritis, atopic dermatitis, psoriasis and BD.
1 Figure 3c shows that TNFa expression was lower in IL-6 siRNA-injected BD mice than in scramble-injected BD mice, evidenced by ELISA. By ELISA, the TNFa expression levels were 72.3 ± 40.1 pg ml
for the scramble-injected BD (n ¼ 9) compared with 30.1 ± 18.3 pg ml À1 in the IL-6 siRNA-injected BD (n ¼ 8) and 6.2±5.6 pg ml À1 for the BDN (n ¼ 8) (scrambleinjected BD vs IL-6 siRNA-injected BD: P ¼ 0.015). TGFb has been shown to be required for regulatory T-cell activity and for inducing CD4+CD25+ Foxp3+ regulatory T cells. 20 As shown in Figure 3d , TGFb was higher in BDN mice (10.4 ± 7.3 ng ml À1 , n ¼ 6) compared with BD mice (4.9±2.1 ng ml
, n ¼ 7), although statistically not significant (P ¼ 0.07). In IL-6 siRNA-injected BD mice (n ¼ 8), TGFb was 7.0±1.8 ng ml
. This level was at a 42.9% higher level compared with that in BD mice and was statistically significant (P ¼ 0.035).
Regulatory T cells were related to the IL-6 level in BD mice
Foxp3, a member of the forkhead/winged-helix family of transcriptional regulators, functions as the master regulator in the development and function of regulatory T cells. 21 Positive splenocytes were higher in IL-6 siRNAinjected BD mice (34.8 ± 15.7%) than in scramble siRNAinjected BD mice (5.3±7.0%) (P ¼ 0.0009, n ¼ 9 in each group) (Figure 4a ). To explore the relationship between CD4+CD25+ regulatory T cells and IL-6 level in BD, in vitro developed CD4+CD25+ regulatory T cells were adoptively transferred to BD mice. Two weeks later, BD mice were killed, and IL-6 levels in serum were analyzed by ELISA (Figure 4b The serum levels of IL-6 were serially measured at days 0, 1, 2 and 3 after IL-6 siRNA injection (n ¼ 5 per group). After 3 days, a rebound was observed. The mice used were 12 months old. (c) The comparison of single administration and repeat administration of IL-6 siRNA. The mice used were 14 months old. In the repeat injection, mice were injected four times at 3-day intervals with 1.5 mg IL-6 siRNA. The serum was collected by retro-orbital bleeding technique before injection and 2 days later after last injection of IL-6 siRNA. The IL-6 level was analyzed by ELISA.
IL-6 siRNA in HSV-induced inflammation J Shim et al of BD mice (n ¼ 6) was 171.9 ± 133.0 pg ml À1 and that of BDN mice (n ¼ 6) was 19.6±19.9 pg ml À1 . 2Â 10 5 CD4+CD25+ cells transferred group (n ¼ 10) and 7 Â 10 5 cells transferred BD (n ¼ 6) were statistically significant compared with not transferred BD (P ¼ 0.01 and P ¼ 0.03). The severity score of symptoms was compared between before the transfer and 2 weeks after CD4+CD25+ cell transfer (Figure 4c ). After adoptive transfer, the severity scores of the CD4+CD25+ cells transferred BD mice were lower than that before the transfer: in the 0.4 Â 10 5 CD4+CD25+ cells transferred group, the severity score was decreased from 2.8±0.84 to 1.8 ± 1.3 (n ¼ 5, P ¼ 0.034); in the 2 Â 10 5 CD4+CD25+ cells transferred group, the severity score was changed from 2.5 ± 0.8 to 1.3 ± 0.97 (n ¼ 12, P ¼ 0.003); and in the 7 Â 10 5 CD4+CD25+ cells transferred group, it was 3.5±0.58 before the transfer and 1.5 ± 1.0 after the transfer (n ¼ 4, P ¼ 0.013). The difference of severity score was statistically significant in all the three groups. As control experiments, CD4+CD25À cells were transferred and the severity score changed from 2.1 ± 0.38 to 1.7 ± 0.95 (n ¼ 7,
IL-6 siRNA improved the BD symptoms
Interleukin-6 siRNA at a dose of 1.5 mg was intraperitoneally applied to BD mice with transfection reagent to determine whether IL-6 siRNA could improve the BD symptoms in mice. When BD symptoms appeared, siRNA was injected four times with 3-day intervals, and the mice were subsequently observed for 2 weeks (n ¼ 9). The changes in symptoms are shown in Figure 5a . The BD symptoms, such as oral ulcer, skin ulcer, scrotum enlargement, genital inflammation, arthritis and so on, were improved. IL-6 siRNA effectively decreased BD symptoms in seven of nine cases (77.8%), but scramble siRNA treatment decreased BD symptoms in two of six cases (33.3 %) (Po0.1). The severity score changed from 3.1±1.05 to 1.7±0.87 after IL-6 siRNA injection (P ¼ 0.005), and from 2.5 ± 0.84 to 2.0 ± 1.41 after scramble siRNA injection (P ¼ 0.203) (Figure 5b) , showing that the severity score of IL-6 siRNA-injected mice was decreased statistically significantly compared with scramble siRNAinjected mice. To know the duration of effectiveness of IL-6 siRNA in BD mice, they were traced for 6 weeks after three times injection with 3-day intervals (n ¼ 5). The severity score was 2.6±1.34 before the injection, 1.4±0.58 at 3 weeks and 1.8 ± 0.44 at 6 weeks. The severity score of scramble siRNA-injected BD mice changed from 2.2 ± 0.45 to 2.8 ± 0.45 at 3 weeks and to 3.33 ± 1.8 at 6 weeks (n ¼ 5). The significance of the severity score between IL-6 siRNAinjected and scramble siRNA-injected mice was Po0.05 at 3 and 5 weeks (Figure 5c ). 
IL-6 siRNA injection into BD mice downregulated IL-17 expression
It is known that IL-6 in combination with TGFb induces Th17 cell generation from naive T cells and inhibits TGFb-induced Foxp3 expression. 19, 22 To study whether reduced IL-6 by siRNA could influence the expression of Th17, IL-17 protein production in IL-6 siRNA-injected BD mice was measured by ELISA. The IL-17 protein levels were 24.8 ± 9.3 pg ml À1 in the IL-6 siRNA-injected BD group (n ¼ 9) compared with 32.0±15.3 pg ml À1 for the scramble injected BD group (n ¼ 8) (P ¼ 0.23) and 38.0±20.5 pg ml À1 for the not injected BD group (n ¼ 12) (BD vs IL-6 siRNA-injected BD: P ¼ 0.09). In BDN mice (n ¼ 9), the IL-17 protein level was 22.8±3.9 pg ml
À1
, and this was significantly lower than that in BD mice (P ¼ 0.03). IL-6 siRNA injection into BD mice downregulated the serum level of IL-17, although the P-value was not significant. mRNA expression of IL-17A and IL-17F in spleen tissues from the IL-6 siRNA-injected group and the scramble-siRNA injected group showed similar patterns to ELISA results (Figure 6a ).
IL-23 was downregulated in IL-6 siRNA-injected BD mice
Interleukin-23 is a cytokine secreted by cells of the innate immune system and is associated with increased IL-17 production. 23 IL-12 and IL-23 are members of a small family of proinflammatory heterodimeric cytokines, 24 and both cytokines share a common p40 subunit that is covalently linked either to a p35 subunit to form IL-12 or to a p19 subunit to form IL-23. 25 As the serum level of IL-17 was reduced by IL-6 siRNA, IL-23p40 in the serum of IL-6 siRNA-injected BD mice was determined to examine whether IL-23 was influenced during IL-17 inhibition by IL-6 siRNA. Figure 6b shows that IL-23p40 was significantly higher (1751.4±274.9 pg ml
) (P ¼ 0.002), and that IL-6 siRNAinjected BD mice (n ¼ 9) downregulated the IL-23p40 (1227.4±511.3 pg ml
À1
) compared with scramble-injected BD mice (P ¼ 0.03). IL-23p19 mRNA expression in BD mice was stronger than that in BDN mice, but IL-6 siRNA injection did not influence the expression of IL-23p19 ), tumor necrosis factor-b (TGFb) (2 ng ml À1 ), anti-CD3 (0.1 mg ml À1 ) and anti-CD28 antibody (0.2 mg ml À1 ) in complete RPMI medium (heatinactivated 10% fetal bovine serum, 1% antibiotics). CD4+ T cells were isolated from cultured splenocytes with MACS separation columns. CD4+CD25+ and CD4+CD25À T cells were sorted from CD4+ T cells using the CD4+CD25+ Regulatory T cell Isolation kit. The sorted CD4+CD25+ cells were adoptively transferred to mice through a tail vein. Two weeks later, the mice were killed and IL-6 in the serum was analyzed by ELISA. (c) The severity score was compared between before and after 2 weeks of the CD4+CD25+ cells adoptive transfer. The difference of the severity score was statistically significant in all three groups (0.4 Â 10 5 , 2 Â 10 5 and 7 Â 10 5 cells transfer). As control experiments, 2 Â 10 5 CD4+CD25À cells were transferred and the severity score of the control experiment was not statistically significant (n ¼ 5-12 in each bar).
IL-6 siRNA in HSV-induced inflammation J Shim et al mRNA in peritoneal macrophages from BD mice. IL-23 receptor mRNA expression was also strongly expressed in BD mice compared with BDN mice. IL-6 siRNA injection could downregulate IL-23 receptor mRNA in BD mice.
Discussion
The present results showed that BD mice had markedly elevated serum IL-6 levels compared with BDN mice.
Furthermore, IL-6 siRNA reduced the protein levels of IL-6 in vitro macrophage culture, and the serum level of IL-6 was lower in siRNA-treated subjects in vivo, compared with scramble siRNA-treated controls. In IL-6 siRNA-treated BD mice, the expression of RORgt and TNFa mRNA was lower compared with scramble siRNA-treated BD mice. The serum levels of TNFa and TGFb were also affected. Foxp3-positive splenocytes were higher in IL-6siRNA-injected BD mice than in The comparison of the severity score before and after injection of IL-6 siRNA (n ¼ 9), and scramble siRNA (n ¼ 6). The severity score was decreased and statistically significant in IL-6 siRNA-injected BD mice compared with scramble siRNA-injected BD mice. (c) To know the longevity of effectiveness of IL-6 siRNA in BD mice, IL-6 siRNA was injected into BD mice peritoneum three times with 3-day intervals (n ¼ 5). The severity score decreased over 6 weeks after IL-6 siRNA injection compared with scramble injection (n ¼ 5). At weeks 3 and 5, the difference of the severity score between the IL-6 siRNA group and the scramble siRNA-injected group was statistically significant (P ¼ 0.03).
IL-6 siRNA in HSV-induced inflammation J Shim et al scramble siRNA-injected BD mice. Adoptive transfer of CD4+CD25+ cells to BD mice affected serum IL-6 level: CD4+CD25+ cells reduced the serum IL-6 level cell number-dependently in BD mice. After CD4+CD25+ cells transfer, the severity score of BD mice was decreased compared with that before the transfer. However, CD4+CD25-cells transfer did not affect the severity score. Most impressively, the IL-6 siRNAinjected BD mice improved BD symptoms such as oral ulcer, scrotum enlargement, arthritis, skin ulcer and genital inflammation. The severity scores were properly decreased and statistically significant compared with scramble siRNA-injected BD mice. The effect of siRNA was sustained for 6 weeks after the first injection. The serum levels of IL-17 in IL-6 siRNA-injected BD mice were lower than those in scramble-injected BD mice, although the P-value was not significant. The IL-6 siRNA injection into BD mice also decreased serum IL-23p40 levels and IL-23 receptor mRNA.
Overproduction of IL-6 has been shown to play a role in rheumatoid arthritis, juvenile idiopathic arthritis, 26 inflammatory bowel disease 27 and systemic lupus erythematosus. 28 It has been reported that HSV type 1 and type 2 are potent inducers of IL-6, 29 and that IL-6 is released relatively early in the inflammatory response after HSV infection. 30 IL-6 is a pleiotropic cytokine to support a range of functions in the host response to infection. The role of IL-6 in clearance of infections with intracellular bacteria and viruses has been shown through studies with IL-6-deficient mice. 31 Recently, IL-6 has also been shown to be required for an optimal immune response after ocular HSV-1 infection. 32 Furthermore, despite similar viral titers in the eye, the IL-6 knockout mice were less able to survive the infection than their wild-type littermates: Lack of IL-6 enhances susceptibility to HSV infection. 33 In this study, knockdown of IL-6 by siRNA improved the BD symptoms even though this BD mouse model was triggered by HSV inoculation.
Recently, RORgt was reported to be a critical target of IL-6 to generate Th17. 33 Foxp3 inhibits RORgtmediated IL-17A mRNA transcription. 34 Our present results show that the number of Foxp3 positive splenocytes is higher in IL-6 siRNA-injected BD mice than in scramble-injected BD mice. IL-17 serum levels of IL-6 siRNA-injected BD mice were also lower than those of scramble-injected BD mice, and RORgt expression was decreased in the spleen tissues of IL-6 siRNA-injected BD mice. These IL-6 siRNA-injected BD mice also showed downregulated TNFa levels and upregulated TGFb levels in serum. Henness et al. 35 reported that IL-17A augments TNFa-induced IL-6 expression. In our experiment, downregulated IL-6 could reduce TNFa and IL-17 expression. IL-6 siRNA in HSV-induced inflammation J Shim et al Wan et al. 36 reported that IL-6 inhibits CD4+CD25+ T-cell regulatory functions. CD4+CD25+ regulatory T cells have a role in maintaining immunologic selftolerance and lead to the decrease of spontaneous development of various autoimmune diseases.
37 CD4+ CD25+ cells contribute to Th2 polarization by suppressing Th1 response development;
38 TNF receptor-shedding by CD4+CD25+ regulatory T cells inhibits the induction of inflammatory mediators; 39 and blocking of the IL-6 signaling pathway prevents CD4+ T-cell-mediated colitis. 40 All these studies indicate that the downregulation of IL-6 could positively react to improve BD symptoms. Increased regulatory T-cell numbers or function have been associated with improvement of inflammatory symptoms such as multiple sclerosis, experimental autoimmune encephalitis, and diabetes in mice and humans. [41] [42] [43] [44] [45] In this study, the BD mice transferred with CD4+CD25+ regulatory T cells also showed reduced serum IL-6 levels and decreased severity score. In addition, recovering BD mice after injection of IL-6 siRNA showed a significantly high expression of Foxp3+ cells compared with scramble siRNA-injected mice.
It has been reported that the number of Th17 cells induced by IL-6 and TGFb was increased in the presence of TNFa. 46 IL-6 participates in the generation of Th17 cells from naive T cells, and TNFa in combination with TGFb expands the Th17 cells pool. Anti-IL-6 receptor antibody therapy has been found to have a significant therapeutic effect in the treatment of systemic onset juvenile idiopathic arthritis. 47 In our experiment, the BD mice after injection of IL-6 siRNA also showed lower serum IL-17 and lower IL-17A and IL-17F mRNA accompanied with improvement of symptoms. Recent studies suggest that the IL-23/IL-17 axis may play a dominant role in provoking a chronic autoimmune inflammation and is considered to be essential for T-cell-mediated colitis and for promoting inflammation through IL-17 and IL-6. [48] [49] [50] In erythema nodosum-like lesions of BD patients, IL-23p19 mRNA was highly expressed. 51 IL-6 siRNA injection into BD mice affected the expression of IL-23 receptor mRNA.
Interleukin-6 receptor inhibition with anti-IL-6 receptor antibody indicated that IL-6 signaling was inhibited and ameliorated the symptoms in patients with rheumatoid arthritis and Castleman's disease. 52 Anti-IL-6 receptor antibody plus methotrexate therapy is effective in achieving rapid and sustained improvements in signs and symptoms of rheumatoid arthritis in patients. 53 Low-dose methotrexate therapy has a beneficial effect in the treatment of progressive neuropsychiatric BD. 54 IL-6 levels in cerebrospinal fluid were found to be dramatically decreased in all methotrexate-treated patients. Therefore, IL-6 siRNA could be a useful therapeutic agent for patients with high serum levels of IL-6, such as BD, sepsis and rheumatoid arthritis.
In conclusion, in vivo, the serum level of IL-6 was lower in siRNA-treated subjects compared with scrambled siRNA-treated controls. In addition, IL-6 siRNA-injected BD mice improved BD symptoms. The severity scores were accordingly decreased with statistical significance compared with scramble-injected BD mice. Adoptive transfer of CD4+CD25+ cells to BD mice decreased the IL-6 serum levels, dependently of CD4+CD25+ cell number. After CD4+CD25+ cells transfer, the severity score of BD mice was decreased when compared with that before the transfer. Our finding highlights the potential of systemic siRNA for therapeutic gene silencing.
Materials and methods
Preparation of siRNA
Interleukin-6 siRNA was synthesized by Dharmacon Research (Lafayette, CO, USA). The synthesized sequences of IL-6 siRNA were 5 0 -AGUCGGAGG CUUAAUUACA-3 0 , 5 0 -CAGGAAAUUUGCCUAUUGA-3 0 , and 5 0 -UAAGGACCAAGACCAUCCA-3 0 . Scramble siRNA was synthesized and used as a negative control for siRNA. For injection into mice, the IL-6 siRNA mixture with transfection reagent jetPEI (PolyPlus-transfection, Llkirch, France) was used, 55 and oligofectamine (GibcoInvitrogen, Rockville, MD, USA) was used for in vitro transfection. 56 
Reagents and cell culture
Mice used in our experiments were 4-to 5-week-old ICR male mice. Macrophages were collected by peritoneal lavage with cold phosphate-buffered saline. The cells were washed, seeded at a density of 1.5 Â 10 6 cells per 6-well culture plate, and then incubated overnight before transfection. Transfection reagent-siRNA complexes were prepared by incubating siRNA with oligofectamine and then added to the cells. After 24-48 h of stimulation, cells were analyzed by RT-PCR and ELISA. 0 -GAGTTCTCCATGCCTAGGGA-3 0 . Amplified PCR products were visualized on 1.8% agarose gels.
Reverse transcription-PCR
Real-time PCR
For real-time SYBR Green RT-PCR, the 20 ml reaction contained 10 ml of 2 Â Quantitect SYBR Green Master Mix (Qiagen, Valencia, CA, USA) containing a hot start Taq polymerase, 0.4 ml mix of two reverse transcriptases, 0.5 ml (10 ng ml
À1
) of template and 0. 
Animal experiments
ICR male mice (4-to 5-week-old) were infected with HSV type 1 (1 Â 10 6 p.f.u. ml
À1
, F strain) grown in Vero cells, as described earlier. 15 Virus inoculation was performed twice with 10-day intervals, followed by 16 weeks of observation. Animals were handled in accordance with a protocol approved by the animal care committee of the Ajou University School of Medicine. For each mouse, 1.5 mg of IL-6 siRNA in 200 ml of 5% glucose solution was intraperitoneally injected four times with 3-day intervals and subsequently observed for 2-6 weeks. During 6 weeks, the severity score was recorded and compared with the scramble-injected group.
BD-like symptoms
Manifestations in mice after HSV inoculation involved multiple symptoms. 15 Of the total number of HSVinjected mice, 15% developed BD-like symptoms. The disappearance of symptoms, or more than a 20% decrease in the lesion size, were classified as effective. The severity score of BD was followed by determination of the value of BD activity index, as outlined in the BD Activity Form (www.behcet.ws/pdf/BehcetsDiseaseActivityForm.pdf). Among the symptoms in patients, mouth ulceration, genital ulceration, erythema, skin pustules, skin ulceration, arthritis of the joints, diarrhea, red eye (right, left), reduced vision (right, left), loss of balance, discoloration and swelling of the face were selected and analyzed in the BD mouse model. The score of each symptom is one, and after the score was added up, the total was used in determining the severity score of BD.
ELISA
Serum was analyzed using the commercial ELISA kits for the detection of mouse IL-6 (R&D system, Minneapolis, MN, USA), TNFa (R&D system), TGFb (R&D system), IL-17 (R&D system) and IL-23p40 (R&D system). ELISA was carried out according to the manufacturer's instructions. The ELISA reader was a Bio-Rad model 170-6850 microplate reader at a wavelength of 450 nm.
Flow cytometry
For the intracellular detection of Foxp3, the PE-Cy5-antimouse Foxp3 staining set was (eBioscience; San Diego, CA, USA) used according to the manufacturer's instructions. Briefly, cells were fixed using Fix/perm buffer after washing with 1 Â permeabilization buffer, and then incubated with PE-Cy5-conjugated anti-mouse Foxp3 Ab. Stained cells were analyzed by a flow cytometer (FACS Vantage; Becton Dickinson, San Jose, CA, USA) with X10 000 gated lymphocytes. Negative isotype control was used to distinguish stained from unstained cells.
CD4+CD25+ T-cell isolation, proliferation and adoptive transfer
Splenocytes were isolated from normal healthy mice and cultured for 2 days in the presence of mouse rIL-2 (20 U ml À1 ), TGFb (2 ng ml À1 ), anti-CD3 (0.1 mg ml
À1
) and anti-CD28 (0.2 mg ml À1 ) in complete RPMI medium (with 10% fetal bovine serum, 1% antibiotics). CD4+ T cells were isolated from cultured splenocytes with MACS separation columns (Miltenyi Biotec, Bergisch Gladbach, Germany). CD4+CD25+ and CD4+CD25À T cells were sorted from CD4+ splenocytes using the CD4+CD25+ Regulatory T cell Isolation kit (Miltenyi Biotec). The sorted CD4+CD25+ cells were adoptively transferred to mice through a tail vein.
Statistical analysis
All data are represented as mean±s.e. Statistical differences between the experimental groups were determined using the Student's t-test and Bonferroni correction. Statistical analysis was performed using the MedCalc version 9.3.0.0.
